PRLog - June 11, 2014 - LONDON -- It is estimated that one in three people in the UK will suffer from allergies at some time in their lives and that number is on the increase. In addition to this, official figures released by the Health and Social Care Information Centre (HSCIC) report that the number of people in England admitted to hospital because of allergies rose by 7.7% in the 12 months to February 2014.* Source: http://www.webmd.boots.com/
With the urgent need for new therapies, SMi’s inaugural Allergies conference will gather leading members of the industry to discuss current advances in drug development, research, best practice, novel approaches in treatment and much more.
Allergies 2014 will ask the questions: What is the future of allergen specific immunotherapy?
This is just a snippet of what will be covered in the packed conference agenda. To download the brochure visit http://www.smi-
With only 4 weeks remaining, SMi’s inaugural allergies conference is filling up fast. Some of those who have confirmed attendance include: Nestle, Danone, Allergy Therapeutics, Allergy Biomay AG, GSK, Nutricia Research and Quintiles
Key Speakers Include:
Chiara Nembrini, Research Scientist in Allergy, Nestle Research Center
Daphne Tsitoura, Senior Medical Director, Clinical Drug Development / Discovery Medicine, GSK
Professor Alf Lindberg, Chief Scientific Director, Swecure AB
Dr Rainer Henning, CEO, Biomay AG
Ian Strickland, Research Scientist, MedImmune
Dr Glenis Scadding, Honorary Consultant Allergist & Rhinologist, Royal National Throat, Nose and Ear Hospital
Professor Rudolf Valenta, Professor for Allergology, Medical University of Vienna
To see the full speaker line-up visit: http://www.smi-
Who Should Attend?
"Anyone interested in the latest updates in the field at the interface between industry and clinical research...learn how the different entities have several approaches for allergy prevention and treatment." Nestle
9th & 10th July 2014
Holiday Inn, Regents Park, London UK